{"id":64838,"date":"2026-05-09T15:06:24","date_gmt":"2026-05-09T07:06:24","guid":{"rendered":"https:\/\/flcube.com\/?p=64838"},"modified":"2026-05-09T15:06:25","modified_gmt":"2026-05-09T07:06:25","slug":"mabwell-bioscience-secures-fda-clearance-for-9mw5211-in-ibd-advances-multi-indication-autoimmune-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64838","title":{"rendered":"Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline"},"content":{"rendered":"\n

Mabwell (Shanghai) Bioscience Co., Ltd.<\/strong> (SHA: 688062<\/a>, HKG: 2493<\/a>) announced it has received clinical clearance from the U.S. Food and Drug Administration (FDA)<\/strong> to advance 9MW5211<\/strong>, its highly specific depleting antibody, into clinical development for inflammatory bowel disease (IBD)<\/strong>. Simultaneously, the company confirmed that clinical filings for 9MW5211 across multiple indications\u2014including multiple sclerosis (MS)<\/strong> and IBD<\/strong>\u2014have been accepted for review by Chinese regulatory authorities.<\/p>\n\n\n\n

Drug Profile & Development Status<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Compound<\/strong><\/td>9MW5211<\/td><\/tr>
Mechanism<\/strong><\/td>Highly specific depleting innovative antibody<\/td><\/tr>
Target Indications<\/strong><\/td>Inflammatory bowel disease (IBD), multiple sclerosis (MS), and other autoimmune diseases<\/td><\/tr>
Development Stage<\/strong><\/td>FDA-cleared for IBD trials; Chinese filings under review for multiple indications<\/td><\/tr>
Origin<\/strong><\/td>Independently developed by Mabwell Bioscience<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Mechanism of Action & Engineering Advantages<\/h2>\n\n\n\n

9MW5211 is engineered to precisely intervene in key pathological mechanisms mediated by abnormal immune cells in autoimmune diseases. Through multiple rounds of molecular engineering optimization, the antibody demonstrates:<\/p>\n\n\n\n